Quarterly report · Q3
2934.TEDINET S100UXBC
Period2023-06-01 → 2024-02-29
Filed2024-12-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Amends S100T9GJ. Amended by S100UXGM (2024-12-11).
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.4bn | 2023-06-01 → 2024-02-29 | Cons. | Net sales |
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.7bn | 2022-06-01 → 2023-02-28 | Cons. | Net sales |
| Operating income | −¥542m | 2023-06-01 → 2024-02-29 | Cons. | Operating income |
| Operating income | −¥718m | 2022-06-01 → 2023-02-28 | Cons. | Operating income |
| Ordinary income | −¥552m | 2023-06-01 → 2024-02-29 | Cons. | Ordinary income |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥737m | 2022-06-01 → 2023-02-28 | Cons. | Ordinary income |
| Profit before tax | −¥554m | 2023-06-01 → 2024-02-29 | Cons. | Income before income taxes |
| Profit before tax | −¥738m | 2022-06-01 → 2023-02-28 | Cons. | Income before income taxes |
| Net income (owners) | −¥638m | 2023-06-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥615m | 2022-06-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥632m | 2023-06-01 → 2024-02-29 | Cons. | Profit loss |
| Net income | −¥577m | 2022-06-01 → 2023-02-28 | Cons. | Profit loss |
| Total assets | ¥8.7bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥7.2bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥7.8bn | at 2023-02-28 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.9bn | at 2024-02-29 | Cons. | Liabilities |
| Total liabilities | ¥4.5bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.8bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.0bn | at 2023-02-28 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2024-02-29 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2023-05-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-131.13 | 2023-06-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-71.25 | 2023-12-01 → 2024-02-29d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-133.6 | 2022-06-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-55.9 | 2022-12-01 → 2023-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 29.2% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.0% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2024-02-29 | −¥172m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2024-02-29 | −¥172m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2024-02-29 | −¥438m |
| jpcrp040300-q3r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2024-02-29 | ¥4.2bn |
| jpcrp040300-q3r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2024-02-29 | ¥4.1bn |
| jpcrp040300-q3r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2024-02-29 | ¥165m |
| jpcrp040300-q3r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2024-02-29 | ¥27m |
| jpcrp040300-q3r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2024-02-29 | ¥3.0bn |
| jpcrp040300-q3r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2024-02-29 | ¥3.0bn |
| jpcrp040300-q3r_E33800-000Healthcare Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2024-02-29 | ¥150,000 |
| jpcrp040300-q3r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2024-02-29 | −¥72m |
| jpcrp040300-q3r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2024-02-29 | ¥5.3bn |
| jpcrp040300-q3r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2024-02-29 | ¥5.3bn |
| jpcrp040300-q3r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2024-02-29 | ¥7m |
| jpcrp040300-q3r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2024-02-29 | −¥59m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2024-02-29 | ¥12.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2024-02-29 | ¥12.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2024-02-29 | ¥172m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2024-02-29 | −¥103m |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2023-02-28 | −¥139m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2023-02-28 | −¥139m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-02-28 | −¥385m |
| jpcrp040300-q3r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥4.0bn |
| jpcrp040300-q3r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥3.9bn |
| jpcrp040300-q3r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-02-28 | ¥139m |
| jpcrp040300-q3r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥19m |
| jpcrp040300-q3r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥3.0bn |
| jpcrp040300-q3r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥3.0bn |
| jpcrp040300-q3r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥224m |
| jpcrp040300-q3r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥5.8bn |
| jpcrp040300-q3r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥5.8bn |
| jpcrp040300-q3r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-02-28 | ¥458,000 |
| jpcrp040300-q3r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-02-28 | −¥576m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2023-02-28 | ¥12.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2023-02-28 | ¥12.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2023-02-28 | ¥139m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2023-02-28 | −¥333m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 352
| Item | Context | Value | Unit |
|---|---|---|---|
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |